IDRA 008

Drug Profile

IDRA 008

Alternative Names: IDRA-008

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Liver disorders

Most Recent Events

  • 15 Mar 2017 Idera announces intention to submit IND for IDRA 008 in 2018
  • 15 Mar 2017 Idera plans Phase I clinical trial for IDRA 008 in 2018
  • 15 Feb 2017 Idera Pharmaceuticals has patent protection for third generation antisense (3GA) compounds and antisense technology in USA and in countries outside USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top